PREDNISOLONE SODIUM PHOSPHATE
Clinical safety rating: avoid
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
Agonist of glucocorticoid receptors, leading to anti-inflammatory and immunosuppressive effects via inhibition of phospholipase A2, reduction of pro-inflammatory cytokines, and suppression of immune cell activity.
| Metabolism | Hepatic, primarily via CYP3A4, including reduction to inactive metabolites (e.g., prednisolone metabolized to prednisone interconversion). |
| Excretion | Renal excretion of inactive metabolites (primarily prednisolone) accounts for >80% of elimination; less than 10% excreted unchanged. Biliary/fecal excretion is negligible (<5%). |
| Half-life | Terminal elimination half-life is 2.1–3.5 hours in adults (mean 2.6 h). Clinical context: Short half-life supports twice-daily dosing for most conditions; prolonged in hepatic impairment (up to 8 h). |
| Protein binding | 70–90% bound primarily to corticosteroid-binding globulin (CBG; transcoritin) and albumin. Binding is concentration-dependent and saturable at high doses. |
| Volume of Distribution | 0.4–1.0 L/kg. Clinical meaning: Moderate distribution suggests extensive extravascular tissue uptake; increased in inflammatory states and decreased in obesity. |
| Bioavailability | Oral: 70–90% (immediate-release tablets). Ophthalmic: <0.1% systemic absorption due to extensive first-pass metabolism. Rectal: 20–30%. |
| Onset of Action | Oral: 1–2 hours. Intravenous: rapid (within minutes). Ophthalmic: 30–60 minutes. Rectal: 30–60 minutes. |
| Duration of Action | Oral/IV: 18–36 hours (single dose). Clinical notes: Duration exceeds half-life due to slow receptor dissociation. Longer duration with repeated dosing due to tissue accumulation. |
| Molecular Weight | 484.39 |
Initial dose: 5-60 mg orally or intravenously once daily or divided every 12-24 hours; range 5-60 mg/day. For acute conditions, 40-60 mg once daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No specific dose adjustment recommended; monitor fluid/electrolytes in severe impairment. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B/C: reduce dose by 50% or use alternative due to decreased clearance. |
| Pediatric use | 0.5-2 mg/kg/day orally or intravenously divided every 6-12 hours; maximum 60-80 mg/day. |
| Geriatric use | Start at lower end of dosing range (e.g., 5-15 mg/day); monitor for hyperglycemia, osteoporosis, immunosuppression. |
| 1st trimester | Corticosteroids are associated with a small increased risk of oral clefts when used in the first trimester. Use only if clearly needed. |
| 2nd trimester | May be used if benefit outweighs risk; monitor for fetal growth restriction. |
| 3rd trimester | Use cautiously; may cause neonatal adrenal suppression or low birth weight. |
Clinical note
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
| FDA category | Positive |
| Placental transfer | Prednisolone crosses the placenta but is partially inactivated by 11β-hydroxysteroid dehydrogenase type 2. Only about 10% of maternal dose reaches the fetus. |
| Breastfeeding |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | immunosuppression |
| Serious Effects |
Systemic fungal infectionsKnown hypersensitivity to prednisolone or any component
| Precautions | Increased risk of infections due to immunosuppression, Adrenal suppression with prolonged use, Corticosteroid-induced osteoporosis, Gastrointestinal perforation risk in patients with certain conditions (e.g., diverticulitis, peptic ulcer), Exacerbation of diabetes mellitus, Psychiatric disturbances (e.g., euphoria, depression), Kaposi's sarcoma reported with corticosteroid use |
| Food/Dietary | Avoid grapefruit and its juice as they may inhibit CYP3A4 and increase prednisolone levels. Limit high-sodium foods and consider potassium-rich intake (e.g., bananas, oranges) to counteract electrolyte wasting. Reduce refined carbohydrate consumption to minimize hyperglycemia. |
Loading safety data…
| Prednisolone enters breast milk in low doses (less than 1% of maternal dose). Consider timing doses after breastfeeding and use lowest effective dose. Monitor infant for possible adrenal suppression. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | First trimester: Increased risk of cleft lip/palate (odds ratio ~3.4) with systemic exposure. Second/third trimester: Risk of intrauterine growth restriction, preterm birth, and adrenal suppression in neonate. Potential for maternal glucose intolerance and preeclampsia. |
| Fetal Monitoring | Monitor maternal blood glucose (gestational diabetes), blood pressure (preeclampsia), and fetal growth via ultrasound every 4-6 weeks in second/third trimester. Assess neonatal adrenal function if chronic maternal use. |
| Fertility Effects | May cause inhibition of ovulation or menstrual irregularities due to hypothalamic-pituitary-adrenal axis suppression. Reversible upon dose reduction or discontinuation. No evidence of permanent impairment. |
| Clinical Pearls | Prednisolone sodium phosphate is a water-soluble prodrug rapidly converted to prednisolone, making it suitable for IV or IM use in acute settings. Monitor for hyperglycemia in diabetic patients; may require insulin adjustment. Taper dose to avoid adrenal insufficiency after prolonged use (>3 weeks). Avoid live vaccines during therapy. Use with caution in patients with ocular herpes simplex due to risk of corneal perforation. |
| Patient Advice | Take with food or milk to reduce gastrointestinal irritation. · Do not stop abruptly; follow tapering schedule exactly as prescribed. · Report signs of infection (fever, sore throat, cough) promptly. · Wear medical alert ID for corticosteroid use in emergencies. · Limit salt intake and monitor for swelling or weight gain. · Avoid live vaccines (e.g., MMR, nasal flu) while on this medication. · Notify your doctor if you have diabetes, hypertension, or peptic ulcer disease prior to starting therapy. · Store at room temperature, protect from light, and use within 90 days of opening bottle. |